Hepatocellular carcinoma treatment over sorafenib: Epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 12, 2015, Pages 1623-1635

  Gnoni, Antonio ^a   Santini, Daniele ^b   Scartozzi, Mario ^c   Russo, Antonio ^d   Licchetta, Antonella ^a   Palmieri, Vincenzo ^e   Lupo, Luigi ^e   Faloppi, Luca ^f   Palasciano, Giuseppe ^e   Memeo, Vincenzo ^e   Angarano, Gioacchino ^e   Brunetti, Oronzo ^g   Guarini, Attilio ^g   Pisconti, Salvatore ^a   Lorusso, Vito ^g   Silvestris, Nicola ^g  

^a Hospital of Taranto   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e UNIVERSITY OF BARI   (Italy)

^f UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^g NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

DNA methylation; epigenetics; hepatocellular carcinoma; microRNAs; platelets; sorafenib; tivantinib; VEGF

Indexed keywords

BIOLOGICAL MARKER; DNA; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MICRORNA; PLATELET DERIVED GROWTH FACTOR; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

DNA METHYLATION; DRUG TARGETING; EPIGENETICS; HUMAN; LIVER CELL CARCINOMA; MACROPHAGE; MOLECULAR EVOLUTION; MOLECULARLY TARGETED THERAPY; REVIEW; THROMBOCYTE; TUMOR MICROENVIRONMENT; ANALOGS AND DERIVATIVES; ANIMAL; CARCINOMA, HEPATOCELLULAR; DRUG DESIGN; GENETIC EPIGENESIS; GENETICS; LIVER NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DNA METHYLATION; DRUG DESIGN; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; LIVER NEOPLASMS; MICRORNAS; MOLECULAR TARGETED THERAPY; NIACINAMIDE; PHENYLUREA COMPOUNDS; TUMOR MICROENVIRONMENT;

EID: 84952876608     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2015.1071354     Document Type: Review

References (123)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90
2. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 2014;63(5):844-55
3. Rolfo C, Bronte G, Sortino G, et al. The role of targeted therapy for gastrointestinal tumors. Expert Rev Gastroenterol Hepatol 2014;8(8):875-85
4. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90
5. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol 2009;10(1):25-34
6. Bronte F, Bronte G, Cusenza S, et al. Targeted therapies in hepatocellular carcinoma. Curr Med Chem 2014;21(8):966-74
7. Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013;31(32):4067-75
8. Johnson PJ, Qin S, Park JW, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013;31(28):3517-24
9. Llovet JM, Decaens T, Raoul JL, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenibfailed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013;31(28):3509-16
10. Villanueva A, Llovet JM. Targeted terapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-26
11. Zhu AX, Abrams TA, Miksad R, et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer 2011;117:5094-102
12. Shiah HS, Chen CY, Dai CY, et al. Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. Aliment Pharmacol Ther 2013;37(1):62-73
13. De Simone P, Crocetti L, Pezzati D, et al. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Transplant Proc 2014;46(1):241-4
14. Bronte G, Terrasi M, Rizzo S, et al. EGFR genomic alterations in cancer: prognostic and predictive values. Front Biosci (Elite Ed) 2011;3:879-87
15. Di Fede G, Bronte G, Rizzo S, et al. Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of nonhaematological tumors. Expert Opin Biol Ther 2011;11(11):1433-45
16. Bronte G, Sortino G, Passiglia F, et al. Monoclonal antibodies for the treatment of nonhaematological tumours: update of an expanding scenario. Expert Opin Biol Ther 2014;1-15
17. Bronte G, Cicero G, Cusenza S, et al. Monoclonal antibodies in gastrointestinal cancers. Expert Opin Biol Ther 2013;13(6):889-900
18. Alberts SR, Fitch TR, Kim GP, et al. Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II north central cancer treatment group (NCCTG) Clinical Trial. Am J Clin Oncol 2012;35(4):329-33
19. Cainap C, Qin S, Huang W-T, et al. Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2013;(suppl 4); abstr 249
20. Fang P, Hu J, Cheng Z, et al. Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials. PLoS One 2012;7(12):e49717
21. Hsu CH, Kang YK, Yang TS, et al. Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study. Oncology 2013;85(1):44-52
22. Santoro A, Rimassa L, Borbath I, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013;14(1):55-63
23. Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457-63
24. Herceg Z, Paliwal A. Epigenetic mechanisms in hepatocellular carcinoma: how environmental factors influence the epigenome. Mutat Res 2011;727:55-61
25. Borel F, Konstantinova P, Jansen PLM. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 2012;56(6):1371-83
26. Pradhan S, Bacolla A, Wells RD, et al. Recombinant human DNA (cytosine-5) methyltransferase. I. Expression, purification, and comparison of de novo and maintenance methylation. J Biol Chem 1999;274(46):33002-10
27. Calvisi DF, Ladu S, Gorden A, et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007;117:2713-22
28. Shin SH, Kim BH, Jang JJ, et al. Identification of novel methylation markers in hepatocellular carcinoma using a methylation array. J Korean Med Sci 2010;25(8):1152-9
29. Jung N, Won JK, Kim BH, et al. Pharmacological unmasking microarray approach-based discovery of novel DNA methylation markers for hepatocellular carcinoma. J Korean Med Sci 2012;27(6):594-604
30. Zhang X, Li HM, Liu Z, et al. Loss of heterozygosity and methylation of multiple tumor suppressor genes on chromosome 3 in hepatocellular carcinoma. J Gastroenterol 2013;48(1):132-43
31. Weber M, Hellmann I, Stadler MB, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007;39(4):457-66
32. Pogribny IP, Muskhelishvili L, Tryndyak VP, Beland FA. The role of epigenetic events in genotoxic hepatocarcinogenesis induced by 2-acetylaminofluorene. Mutat Res 2011;722(2):106-13
33. Yu J, Zhang HY, Ma ZZ, et al. Methylation profiling of twenty four genes and the concordant methylation behaviors of nineteen genes that may contribute to hepatocellular carcinogenesis. Cell Res 2003;13(5):319-33
34. Shim YH, Yoon GS, Choi HJ, et al. p16 Hypermethylation in the early stage of hepatitis B virus-associated hepatocarcinogenesis. Cancer Lett 2003;190(2):213-19
35. Su PF, Lee TC, Lin PJ, et al. Differential DNA methylation associated with hepatitis B virus infection in hepatocellular carcinoma. Int J Cancer 2007;121(6):1257-64
36. Barazani Y, Hiatt JR, Tong MJ, Busuttil RW. Chronic viral hepatitis and hepatocellular carcinoma. World J Surg 2007;31(6):1243-8
37. Kiran M, Chawla YK, Kaur J. Methylation profiling of tumor suppressor genes and oncogenes in hepatitis virus-related hepatocellular carcinoma in northern India. Cancer Genet Cytogenet 2009;195(2):112
38. Chu PY, Yeh CM, Hsu NC, et al. Epigenetic alteration of the SOCS1 gene in hepatocellular carcinoma. Swiss Med Wkly 2010;140:w13065
39. Jung K, Fleischhacker M, Rabien A. Cell-free DNA in the blood as a solid tumor biomarker: a critical appraisal of the literature. Clin Chim Acta 2010;411:1611-24
40. Yang Y, Fan YC, Gao S, et al. Methylated cysteine dioxygenase-1 gene promoter in the serum is a potential biomarker for Hepatitis B virus-related Hepatocellular Carcinoma. Tohoku J Exp Med 2014;232:187-94
41. Li F, Fan YC, Gao S, et al. Methylation of serum insulin-like growth factorbinding protein 7 promoter in hepatitis B virus-associated hepatocellular carcinoma. Genes Chromosomes Cancer 2014;53(1):90-7
42. Nishida N, Arizumi T, Takita M, et al. Quantification of tumor DNA in serum and vascular invasion of human hepatocellular carcinoma. Oncology 2013;84(Suppl 1):82-7
43. Wang J, Qin Y, Li B, et al. Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients. Clin Biochem 2006;39:344-8
44. Sun FK, Fan YC, Zhao J, et al. Detection of TFPI2 methylation in the serum of hepatocellular carcinoma patients. Dig Dis Sci 2013;58(4):1010-15
45. Hirasawa Y, Arai M, Imazeki F, et al. Methylation status of genes upregulated by demethylating agent 5-aza-2′- deoxycytidine in hepatocellular carcinoma. Oncology 2006;71(1-2):77-85
46. Nakamura K, Aizawa K, Nakabayashi K, et al. DNA methyltransferase inhibitor zebularine inhibits human hepatic carcinoma cells proliferation and induces apoptosis. PLoS One 2013;8(1):e54036
47. Cheng JC, Yoo CB, Weisenberger DJ, et al. Preferential response of cancer cells to zebularine. Cancer Cell 2004;6:151-8
48. Mei Q, Chen M, Lu X, et al. An openlabel, single-arm, phase I/II study of lower-dose decitabine based therapy in patients with advanced hepatocellular carcinoma. Oncotarget 2015. [Epub ahead of print]
49. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 2009;136:642-55
50. Gramantieri L, Ferracin M, Fornari F, et al. Cyclin G1 is a target of miR-122a, a MicroRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007;67:6092-9
51. Bushati N, Cohen SM. MicroRNA functions. Annu Rev Cell Dev Biol 2007;23:175-205
52. Caruso S, Bazan V, Rolfo C, et al. MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness? Oncogenesis 2012;1:e32
53. Otsuka M, Kishikawa T, Yoshikawa T, et al. The role of microRNAs in hepatocarcinogenesis: Current knowledge and future prospects. J Gastroenterol 2014;49:173-84
54. D'Anzeo M, Faloppi L, Scartozzi M, et al. The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment. Molecules 2014;19:6393-406
55. Liu WH, Yeh SH, Lu CC, et al. MicroRNA-18a prevents estrogen receptor-alfa expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology 2009;136:683-93
56. Zhang X, Zhang E, Ma Z, et al. Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1. Hepatology 2011;53:1476-85
57. Wang Y, Lu Y, Toh ST, et al. Lethal-7 is down-regulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3. J Hepatol 2010;53:57-66
58. Hou W, Tian Q, Zheng J, et al. MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology 2010;51:1494-504
59. Chang J, Nicolas E, Marks D, et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004;1:106-13
60. Galardi S, Mercatelli N, Giorda E, et al. MiR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 2007;282:23716-24
61. Corsini LR, Bronte G, Terrasi M, et al. The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies. Expert Opin Ther Targets 2012;16(Suppl 2):S103-9
62. Franchina T, Amodeo V, Bronte G, et al. Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer. J Cell Physiol 2014;229(1):97-9
63. Amodeo V, Bazan V, Fanale D, et al. Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense? Expert Opin Ther Targets 2013;17(11):1249-61
64. Li LM, Hu ZB, Zhou ZX, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 2010;70:9798-807
65. Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 2011;29:4781-8
66. Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009;361:1437-47
67. Wei R, Huang G-L, Zhang MY, et al. Clinical significance and prognostic value of microRNA expression signatures in hepatocellular carcinoma. Clin Cancer Res 2013;19:4780-91
68. Tomimaru Y, Eguchi H, Nagano H, et al. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-a/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer 2010;103(10):1617-26
69. Krutzfeldt J, Kuwajima S, Braich R, et al. Specificity, duplex degradation and subcellular localization of antagomirs. Nucl Acids Res 2007;35:2885-92
70. Shibata C, Otsuka M, Kishikawa T, et al. Current status of miRNA-targeting therapeutics and preclinical studies against gastroenterological carcinoma. Mol Cell Ther 2013;1:5
71. Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013;368(18):1685-94
72. Xie K, Liu J, Chen J, et al. Methylation-associated silencing of microRNA-34b in hepatocellular carcinoma cancer. Gene 2014;543(1):101-7
73. ClinicalTrials.gov Identifier: NCT01829971
74. Rodríguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011;17:330-9
75. Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009;27:5410-17
76. Mann BS, Johnson JR, He K, et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res 2007;13:2318-22
77. Ma BB, Sung F, Tao Q, et al. The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. Invest New Drugs 2010;28:107-14
78. Carlisi D, Lauricella M, D'Anneo A, et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAILDISC activation. Eur J Cancer 2009;45:2425-38
79. Yeo W, Chung HC, Chan SL, et al. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J Clin Oncol 2012;30:3361-7
80. Khan O, Fotheringham S, Wood V, et al. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci USA 2010;107:6532-7
81. Zheng Y, Chen H, Yin M, et al. MiR-376a and histone deacetylation 9 form a regulatory circuitry in hepatocellular carcinoma. Cell Physiol Biochem 2015;35(2):729-39
82. Coulon S, Heindryckx F, Geerts A, et al. Angiogenesis in chronic liver disease and its complications. Liver Int 2011;31:146-62
83. Leslie M. Cell biology: beyond clotting: the powers of platelets. Science 2010;328:562-4
84. Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012;366:610-18
85. Matsuo R, Ohkohchi N, Murata S, et al. Platelets strongly induce hepatocyte proliferation with IGF-1and HGF in vitro. J Surg Res 2008;145:279-86
86. Carr BI, Lin CY, Lu SN. Platelet-related phenotypic patterns in hepatocellular carcinoma patients. Semin Oncol 2014;41(3):415-21
87. Carr BI, Guerra V, Giannini EG, et al. for the Italian Liver Cancer (ITA.LI.CA) group. Significance of platelet and AFP levels and liver function parameters for HCC size and survival. Int J Biol Markers 2014;29(3):e215-23
88. Carr BI, Cavallini A, D'Alessandro R, et al. Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro. BMC Cancer 2014;14:43
89. Sitia G. Depletion of neutrophils blocks the recruitment of antigen-nonspecific cells into the liver without affecting the antiviral activity of hepatitis B virusspecific cytotoxic T lymphocytes. Proc Natl Acad Sci USA 2002;99:13717-22
90. Maini MK, Schurich A. Platelets harness the immune response to drive liver cancer. Proc Natl Acad Sci USA 2012;109(32):12840-1
91. Iannacone M, Sitia G, Isogawa M, et al. Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med 2005;11(11):1167-9
92. Cattaneo M. Aspirin and clopidogrel: Efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004;24:1980-7
93. Sitia G. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci USA 2012;109:E2165-72
94. D'Alessandro R, Refolo MG, Lippolis C, et al. Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines. BMC Cancer 2014;14:351
95. Canbay A, Taimr P, Torok N, et al. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003;83:655-63
96. Stout RD, Jiang C, Matta B, et al. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol 2005;175:342-9
97. Zhang W, Zhu XD, Sun HC, et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res 2010;16:3420-30
98. Roderfeld M, Rath T, Lammert F, et al. Innovative immunohistochemistry identifies MMP-9 expressing macrophages at the invasive front of murine HCC. World J Hepatol 2010;2:175-17
99. Liaskou E, Zimmermann HW, Li KK, et al. Monocyte subsets in human liver disease show distinct phenotypic and functional characteristics. Hepatology 2013;57:385-98
100. Budhu A, Forgues M, Ye QH, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006;10:99-111
101. Porta C, Larghi P, Rimoldi M, et al. Cellular and molecular pathways linking inflammation and cancer. Immunobiology 2009;214:761-77
102. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci 2008;13:453-61
103. Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004;104:2224-34
104. Mantovani A, Germano G, Marchesi F, et al. Cancer-promoting tumor-associated macrophages: new vistas and open questions. Eur J Immunol 2011;41:2522-5
105. Capece D, Fischietti M, Verzella D, et al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumorassociated macrophages. Biomed Res Int 2013;2013:187204
106. Mamalis A, Garcha M, Jagdeo J. Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch Dermatol Res 2014;306:511-19
107. Takai H, Ashihara M, Ishiguro T, et al. Involvement of glypican-3 in the recruitment of M2-polarized tumorassociated macrophages in hepatocellular carcinoma. Cancer Biol Ther 2009;8:2329-38
108. Ikeda M, Ohkawa S, Okusaka T, et al. Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma. Cancer Sci 2014;105:455-62
109. Zhu AX, Gold PJ, El-Khoueiry AB, et al. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2013;19:920-8
110. Coscia M, Quaglino E, Iezzi M, et al. Zoledronic acid repolarizes tumourassociated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 2010;14:2803-15
111. ClinicalTrials.gov Identifier: NCT01259193
112. Puche JE, Saiman Y, Friedman SL. Hepatic stellate cells and liver fibrosis. Compr Physiol 2013;3:1473-92
113. Otranto M, Sarrazy V, Bonté F, et al. The role of the myofibroblast in tumor stroma remodeling. Cell Adh Migr 2012;6:203-19
114. Carloni V, Luong TV, Rombouts K. Hepatic stellate cells and extracellular matrix in hepatocellular carcinoma: more complicated than ever. Liver Int 2014;34:834-43
115. Zhao W, Zhang L, Xu Y, et al. Hepatic stellate cells promote tumor progression by enhancement of immunosuppressive cells in an orthotopic liver tumor mouse model. Lab Invest 2014;94:182-91
116. Wright JH, Johnson MM, Shimizu-Albergine M, et al. Paracrine activation of hepatic stellate cells in platelet-derived growth actor C transgenic mice: evidence for stromal induction of hepatocellular carcinoma. Int J Cancer 2014;134:778-88
117. Dooley S, Weng H, Mertens PR. Hypotheses on the role of transforming growth factor-beta in the onset and progression of hepatocellular carcinoma. Dig Dis 2009;27:93-101
118. ClinicalTrials.gov Identifier: NCT01246986
119. ClinicalTrials.gov Identifier: NCT02178358
120. Lai JP, Thompson JR, Sandhu DS, Roberts LR. Heparin-degrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets. Future Oncol 2008;4:803-14
121. Parish CR, Freeman C, Brown KJ, et al. Identification of sulfated oligosaccharidebased inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res 1999;59:3433-41
122. Liu CJ, Chang J, Lee PH, et al. Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence. World J Gastroenterol 2014;20:11384-93
123. ClinicalTrials.gov Identifier: NCT01402908.